FDA approves ramucirumab for gastric cancer or gastroesophageal junction adenocarcinoma

The US Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. It is a fully human monoclonal antibody of the IgG1 class, directed against the vascular endothelial growth factor receptor 2 (VEGFR2). Ramucirumab is intended for patients with unresectable or metastatic disease after treatment with a fluoropyrimidine- or platinum-containing therapy. Read more here.